Compliance Rate
Compliance Rate
100.0%
Compliant submissions
1
Incompliant submissions
0
Total trials
1
My Organizations' Clinical Trials
Showing 279 of 279 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/01/16
End: 03/22/21
Due: 03/22/22
Phase: N/A
Priority: Normal
Start: 01/31/03
End: 01/31/09
Due: 01/31/10
Phase: N/A
Priority: Normal
Start: 04/10/06
End: 07/31/22
Due: 07/31/23
Phase: N/A
Priority: Normal
Start: 09/30/24
End: 08/31/28
Due: 08/31/29
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Glucobrassicin-Brussel Sprout Effect on D10 Phe Metabolism | NCT02999399 | Masonic Cancer Center, University of Minnesota | user2@example.com | None | 2016-12-01 | 2021-03-22 | 2022-03-22 | - | - | 2025-07-14 |
| Bronchial Artery Infusion of Gemcitabine in Treating Patients With Recurrent or Progressive Non-Small Cell Lung Cancer | NCT00619021 | Masonic Cancer Center, University of Minnesota | user2@example.com | None | 2003-01-31 | 2009-01-31 | 2010-01-31 | - | - | 2025-07-14 |
| PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma | NCT00346125 | Masonic Cancer Center, University of Minnesota | user2@example.com | None | 2006-04-10 | 2022-07-31 | 2023-07-31 | - | - | 2025-07-14 |
| Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL | NCT05114837 | Masonic Cancer Center, University of Minnesota | user2@example.com | None | 2024-09-30 | 2028-08-31 | 2029-08-31 | - | - | 2025-07-14 |